Comparing BioCryst Pharmaceuticals (NASDAQ:BCRX) and Polydex Pharmaceuticals (OTCMKTS:POLXF)

Polydex Pharmaceuticals (OTCMKTS:POLXF) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Polydex Pharmaceuticals and BioCryst Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polydex Pharmaceuticals	0	0	0	0	0.00
BioCryst Pharmaceuticals	0	3	10	0	2.77

BioCryst Pharmaceuticals has a consensus target price of $19.64, indicating a potential upside of 109.34%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than Polydex Pharmaceuticals.

Earnings and Valuation

This table compares Polydex Pharmaceuticals and BioCryst Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polydex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BioCryst Pharmaceuticals	$874.84 million	2.69	$263.86 million	$1.20	7.82

BioCryst Pharmaceuticals has higher revenue and earnings than Polydex Pharmaceuticals.

Institutional & Insider Ownership

85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 12.9% of Polydex Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Polydex Pharmaceuticals and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Polydex Pharmaceuticals	N/A	N/A	N/A
BioCryst Pharmaceuticals	30.16%	-84.33%	61.35%

Summary

BioCryst Pharmaceuticals beats Polydex Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About Polydex Pharmaceuticals

Polydex Pharmaceuticals Ltd. is a development stage company, which engages in manufacturing of bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry, and the development, manufacturing, and marketing of biotechnology-based products for the human pharmaceutical market. The firm focuses on Dextran and derivative products, including Iron Dextran and Dextran Sulphate and other specialty chemicals. The company was founded by Thomas C. Usher on June 14, 1979 and is headquartered in Toronto, Canada.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.